Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

This study is currently recruiting participants.
Verified July 2013 by Masonic Cancer Center, University of Minnesota
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00345865
First received: June 28, 2006
Last updated: July 3, 2013
Last verified: July 2013

June 28, 2006
July 3, 2013
November 2005
August 2013   (final data collection date for primary outcome measure)
Percentage of patients achieving complete response [ Time Frame: Day 100, 1 Year, 2 Years ] [ Designated as safety issue: No ]
response rate uses standard definition
Not Provided
Complete list of historical versions of study NCT00345865 on ClinicalTrials.gov Archive Site
  • Prospective validation of the previously published formula used to estimate targeted collection of PBSC [ Time Frame: At end of study ] [ Designated as safety issue: No ]
    Outcome will be descriptive in nature.
  • Immune reconstitution post-transplant in HIV-positive patients compared to HIV-negative patients [ Time Frame: At end of study ] [ Designated as safety issue: No ]
    Outcome will be descriptive in nature.
  • Time to hematopoietic recovery after transplantation [ Time Frame: Days (range) ] [ Designated as safety issue: No ]
    return to ANC (absolute neutrophil count) more than 500 cells/millileter.
  • Duration of response [ Time Frame: At end of study ] [ Designated as safety issue: No ]
    median calculation measured in months (range)
  • Progression-free and overall survival [ Time Frame: 1 Year, 3 Years and 5 Years ] [ Designated as safety issue: No ]
    Includes those patients whose disease does not progress, and those alive at specified timeframes.
Not Provided
Not Provided
Not Provided
 
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Autologous Peripheral Blood Stem Cell Transplant for Patients With Lymphoma

RATIONALE: Drugs used in chemotherapy, such as ifosfamide, etoposide, and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored for peripheral stem cell transplant. Giving more chemotherapy, such as cyclophosphamide, carmustine, and etoposide, and total-body irradiation prepares the patient's bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy. More radiation therapy is given after transplant to kill any remaining cancer cells.

PURPOSE: This phase II trial is studying how well autologous peripheral stem cell transplant works in treating patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.

OBJECTIVES:

Primary

  • Determine the disease-free survival and overall survival of patients with non-Hodgkin's or Hodgkin's lymphoma treated with autologous peripheral blood stem cell transplantation (PBSCT).
  • Verify the safety and efficacy of autologous PBSCT in patients with HIV disease and relapsed lymphoma.

Secondary

  • Evaluate immune reconstitution in HIV-positive patients undergoing autologous PBSCT and compare to immune reconstitution in HIV-negative patients.
  • Predict the adequacy of peripheral blood stem cell (PBSC) harvest prior to flow analysis of a PBSC yield.
  • Determine the time to engraftment for neutrophils and platelets.

OUTLINE:

  • Peripheral blood stem cell (PBSC) mobilization with filgrastim (G-CSF) alone: Patients not requiring further disease reduction receive G-CSF subcutaneously (SC) once daily on days 1-8. Patients undergo PBSC collection by leukapheresis on days 5-8. Patients who do not adequately mobilize with G-CSF alone proceed to chemo-mobilization.
  • Chemo-mobilization: Patients requiring further disease reduction receive 1 of 2 chemo-mobilization regimens.

    • Patients with CD20+ non-Hodgkin's lymphoma (NHL) or lymphocyte predominant Hodgkin's lymphoma: Patients receive rituximab intravenously (IV) over 6-8 hours on day 1, ifosfamide IV over 2 hours and etoposide IV over 30 minutes on days 2-4, and carboplatin IV over 1 hour on day 2. Patients receive G-CSF SC once daily beginning on day 7 and continuing until leukapheresis is completed. Patients undergo PBSC collection by leukapheresis on days 12-15.
    • All other patients: Patients receive ifosfamide IV over 2 hours and etoposide IV over 30 minutes on days 1-3 and carboplatin IV over 1 hour on day 1. Patients receive G-CSF SC once daily beginning on day 5 and continuing until leukapheresis is completed. Patients undergo PBSC collection by leukapheresis on days 12-15.
  • Autologous PBSC transplantation (PBSCT) (Patients with NHL undergoing irradiation): Patients receive cyclophosphamide IV over 2 hours on days -7 and -6. Patients undergo total body irradiation (TBI) twice daily on days -4 to -1. Patients undergo autologous PBSCT on day 0. Patients receive G-CSF SC once daily beginning on day 5 and continuing until blood counts recover.
  • Autologous PBSCT (Patients with Hodgkin's lymphoma or NHL not undergoing irradiation): Patients receive cyclophosphamide IV over 2 hours on days -6 to -3, carmustine IV over 1 hour on day -6, and etoposide IV over 4 hours twice daily on days -6 to -4. Patients undergo autologous PBSCT on day 0. Patients receive G-CSF SC once daily beginning on day 5 and continuing until blood counts recover.
  • Post-transplant irradiation: Patients undergo post-transplant irradiation beginning on day 28. Persisting nodal masses ≥ 2 cm are treated with additional localized external beam irradiation.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Lymphoma
  • Drug: carmustine
    Day -6, 300 mg/m^2 over 1 hour
    Other Name: BNCU
  • Drug: cyclophosphamide

    NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days NHL or HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m^2 over 2 hours daily x 4 days.

    Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing.

    Other Name: Cytoxan
  • Drug: etoposide
    Days -6 through -4, 150 mg/m^2 intravenously over 4 hours every 12 hours for 6 total doses.
    Other Name: VP-16
  • Procedure: peripheral blood stem cell transplantation
    Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and without or without rituximab. Leukapheresis is to begin on Day 5.
    Other Name: PBSC
  • Radiation: irradiation therapy

    Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.

    • > 1000 cGy to whole lung, kidney, or abdominal bath.
    • > 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.
    • > 3600 cGy to whole brain.
  • Biological: G-CSF

    Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.

    Continue G-CSF until absolute neutrophil count (ANC) > 1500/μl x 3 consecutive days.

    If ANC falls <1000/μL, restart G-CSF.

    Other Name: filgrastim
  • Drug: Cytarabine
    100 mg/m^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
    Other Names:
    • Ara-C
    • cytosine arabinoside
    • Cytosar-U
    • Depocyt
  • Experimental: NHL With Radiation
    Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
    Interventions:
    • Drug: cyclophosphamide
    • Procedure: peripheral blood stem cell transplantation
    • Radiation: irradiation therapy
    • Biological: G-CSF
  • Experimental: NHL / HL Without Radiation
    Patients with non Hodgkin's lymphoma or Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
    Interventions:
    • Drug: carmustine
    • Drug: cyclophosphamide
    • Drug: etoposide
    • Procedure: peripheral blood stem cell transplantation
    • Biological: G-CSF
  • Experimental: NHL/HL without radiation or cyclosporine
    Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide or Hodgkin's lymphoma that are ineligible to receive CBV will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
    Interventions:
    • Drug: carmustine
    • Drug: etoposide
    • Procedure: peripheral blood stem cell transplantation
    • Biological: G-CSF
    • Drug: Cytarabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
150
August 2014
August 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Karnofsky performance status: >80% (>60% if poor performance status is related to lymphoma)
  • No evidence of serious organ dysfunction that is not attributable to tumor

    • Infection: Patients with serious uncontrolled infections at the time of transplant will be excluded
  • Hepatitis B: Patients who are carriers of Hepatitis B will be included in this study. These patients are not eligible to receive rituximab as a component of their chemotherapy mobilization.
  • HIV disease. Patients with HIV disease are eligible for this study provided that:

    • Patients will be seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period.
    • Must be on a maximally active anti-HIV regimen
    • CD4+ ≥ 50/μL
    • HIV RNA viral load ≤ 100,000 copies per mL on each of samples 4 weeks apart. The most recent level must be within one month of enrollment.
  • Non-Hodgkin's lymphoma (NHL). Patients with chemo-sensitive histologically confirmed NHL.

    • Precursor B-cell or Precursor T-cell NHL
  • Lymphoblastic lymphoma

    • All patients will be eligible in second or greater complete remission (CR) or first or subsequent partial remission (PR)

      • Mature B-cell Lymphomas: Small lymphocytic lymphoma (SLL) or Chronic Lymphocytic Leukemia (CLL)
      • Follicular Lymphoma
      • Diffuse Large B-cell Lymphoma
      • Mantle Cell Lymphoma
      • Burkitt's/Burkitt's like
      • Mature T-cell lymphoma
  • Patients may be transplanted under this protocol using a syngeneic (identical) twin donor.

Exclusion Criteria:

  • Patients eligible for any higher priority transplant protocols
  • Women who are pregnant or breast feeding
  • Patients with chemotherapy resistant disease
Both
up to 75 Years
No
Contact: Timothy Krepski 612-273-2800 tkrepsk1@fairview.org
United States
 
NCT00345865
2005LS048, UMN-0508M72589, UMN-MT2004-24
Yes
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Not Provided
Principal Investigator: Veronika Bachanova, MD Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP